Case Studies

Challenge Alacrita’s pharma consultants were engaged to conduct a due diligence and valuation of a Phase II dermatology asset.

Challenge A well-capitalized cancer immunotherapy company, operating in a highly competitive field, needed to benchmark its financial status and staff numbers against its peers to help gauge its...

Challenge A European Biotech company with its lead product being developed for a rare oncology disease in Phase 1 wanted to understand how to optimize and evaluate the commercial potential of the...

Challenge A late stage biotech needed a clear understanding of the processes, resource needs and timelines to establish global commercial operations to launch their leading pipeline compound, a...

Challenge A small, Swiss-based biotechnology company with a pre-commercial pipeline of therapeutic antibodies for rare and ultra-rare diseases was preparing to launch its first asset. This company...

Challenge A new academic spin-out company in Europe had acquired the rights to the intellectual property covering a new diagnostic agent. This molecular MRI imaging tool is envisioned to be useful in...

Challenge Dual-energy X-ray absorptiometry (DXA) has been used extensively in clinical trials in osteoporosis. DXA is increasingly being used to examine bone density in trials of drugs that could...

Challenge A start-up company was planning to license an immunomodulatory product from a European pharmaceutical company. The therapy had been unsuccessfully tried in allergic disorders, but the...

Challenge: Alacrita conducted an assessment of an AAV gene therapy for an ophthalmic indication, focusing on market potential, technical and regulatory issues and identification of key risks.

Alzheimer's due diligence Our client, a major pension fund, was considering an investment opportunity in a Phase III neuroscience company. The company was developing a small molecule to provide...